Memory Immune Response: a Major Challenge in Vaccination
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
SAHLGRENSKA AKADEMIN Thymic Studies
Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Akademisk avhandling Som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet kommer att offentligen försvaras i föreläsningssalen våning 3, Guldhedsgatan 10A, Göteborg Tisdagen den 14e maj, klockan 13.00 av Christina Lundqvist Fakultetsopponent: Professor Ludger Klein Ludwig-Maximilians-Universität, Tyskland Avhandlingen baseras på följande delarbeten I. Gudmundsdottir J*, Lundqvist C*, Ijspeert H, van der Slik E, Óskarsdóttir S, Lindgren S, Lundberg V, Berglund M, Lingman-Framme J, Telemo E, van der Burg M, Ekwall O. T-cell receptor sequencing reveals decreased diversity 18 years after early thymectomy. J Allergy Clin Immunol. 2017 Dec;140(6):1743- 1746.e7. doi: 10.1016/j.jaci.2017.08.002. Epub 2017 Sep 1. * These authors contributed equally to this work. II. Lundqvist C*, Camponeschi A*, Visentini M, Telemo E, Ekwall O‡, Mårtensson IL‡. Switched CD21-/low B cells with an antigen-presenting phenotype in the infant thymus. J Allergy Clin Immunol. 2018 Nov 30. pii: S0091-6749(18)31721- 4. doi: 10.1016/j.jaci.2018.11.019. * These authors contributed equally to this work. ‡ These authors contributed equally to this work. III. Lundqvist C, Lindgren S, Cheuk S, Lundberg V, Berglund M, Thörn K, Telemo E, Ekwall O. Characterization of Hassall's corpuscles in the human thymus. Manuscript SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR MEDICIN Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Christina Lundqvist Avdelningen för reumatologi och inflammationsforskning, Institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet Abstract This thesis focuses on the human thymus, a primary lymphoid organ responsible for the maturation of T cells. -
B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells
cells Review B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells Carlo G. Bonasia 1 , Wayel H. Abdulahad 1,2 , Abraham Rutgers 1, Peter Heeringa 2 and Nicolaas A. Bos 1,* 1 Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] (C.G.B.); [email protected] (W.H.A.); [email protected] (A.R.) 2 Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Autoreactive B cells are key drivers of pathogenic processes in autoimmune diseases by the production of autoantibodies, secretion of cytokines, and presentation of autoantigens to T cells. However, the mechanisms that underlie the development of autoreactive B cells are not well understood. Here, we review recent studies leveraging novel techniques to identify and characterize (auto)antigen-specific B cells. The insights gained from such studies pertaining to the mechanisms involved in the escape of tolerance checkpoints and the activation of autoreactive B cells are discussed. Citation: Bonasia, C.G.; Abdulahad, W.H.; Rutgers, A.; Heeringa, P.; Bos, In addition, we briefly highlight potential therapeutic strategies to target and eliminate autoreactive N.A. B Cell Activation and Escape of B cells in autoimmune diseases. Tolerance Checkpoints: Recent Insights from Studying Autoreactive Keywords: autoimmune diseases; B cells; autoreactive B cells; tolerance B Cells. Cells 2021, 10, 1190. https:// doi.org/10.3390/cells10051190 Academic Editor: Juan Pablo de 1. -
Overview of B-Cell Maturation, Activation, Differentiation
Overview of B-Cell Maturation, Activation, Differentiation B-Cell Development Begins in the Bone Marrow and Is Completed in the Periphery Antigen-Independent (Maturation) 1) Pro-B stages B-cell markers 2) Pre B-stages H- an L- chain loci rearrangements surrogate light chain 3) Naïve B-cell functional BCR . B cells are generated in the bone marrow. Takes 1-2 weeks to develop from hematopoietic stem (HSC) cells to mature B cells. Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment. HSC passes through progressively more delimited progenitor-cell stages until it reaches the pro-B cell stage. Pre-B cell is irreversibly committed to the B-cell lineage and the recombination of the immunoglobulin genes expressed on the cell surface Immature B cell (transitional B cell) leaves the bone marrow to complete its maturation in the spleen through further differentiation. Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the Source: Internet same time eliminating self-reactive B cells. B-Cell Activation and Differentiation • Exposure to antigen or various polyclonal mitogens activates resting B cells and stimulates their proliferation. • Activated B cells lose expression of sIgD and CD21 and acquire expression of activation antigens. Growth factor receptors, structures involved in cell-cell interaction, molecules that play a role in the localization and binding of activated B cells Two major types: T cell dependent (TD) T cell independent (TI) B-Cell Activation by Thymus-Independent and Dependent Antigens Source: Kuby T cell dependent: Involves protein antigens and CD4+ helper T cells. -
The TNF-Family Cytokine TL1A Drives IL-13-Dependent Small Intestinal Inflammation
ARTICLES nature publishing group See ARTICLE page 186 The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation F M e y l a n 1 , 6 , Y - J S o n g 1 , 6 , I F u s s 2 , S V i l l a r r e a l 1 , E K a h l e 1 , I - J M a l m 1 , K A c h a r y a 1 , H L R a m o s 3 , L L o 4 , M M M e n t i n k - K a n e 5 , T A W y n n 5 , T - S M i g o n e 4 , W S t r o b e r 2 a n d R M S i e g e l 1 The tumor necrosis factor (TNF)-family cytokine TL1A (TNFSF15) costimulates T cells through its receptor DR3 (TNFRSF25) and is required for autoimmune pathology driven by diverse T-cell subsets. TL1A has been linked to human inflammatory bowel disease (IBD), but its pathogenic role is not known. We generated transgenic mice that constitutively express TL1A in T cells or dendritic cells. These mice spontaneously develop IL-13-dependent inflammatory small bowel pathology that strikingly resembles the intestinal response to nematode infections. These changes were dependent on the presence of a polyclonal T-cell receptor (TCR) repertoire, suggesting that they are driven by components in the intestinal flora. Forkhead box P3 (FoxP3)-positive regulatory T cells (Tregs) were present in increased numbers despite the fact that TL1A suppresses the generation of inducible Tregs. -
Systematic Booster After Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure
Article Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure Perrine Parize 1,*, Jérémie Sommé 2 , Laura Schaeffer 3, Florence Ribadeau-Dumas 1, Sheherazade Benabdelkader 1, Agnès Durand 4, Arnaud Tarantola 1, Johann Cailhol 5, Julia Goesch 5, Lauriane Kergoat 1 , Anne-Sophie Le Guern 6, Marie-Laurence Mousel 2, Laurent Dacheux 1 , Paul-Henri Consigny 5, Arnaud Fontanet 3,7, Beata Francuz 2 and Hervé Bourhy 1 1 Institut Pasteur, Unit Lyssavirus Epidemiology and Neuropathology, National Reference Center for Rabies and WHO Collaborating Centre for Reference and Research on Rabies, 75015 Paris, France; fl[email protected] (F.R.-D.); [email protected] (S.B.); [email protected] (A.T.); [email protected] (L.K.); [email protected] (L.D.); [email protected] (H.B.) 2 Institut Pasteur, Occupational Health Department, 75015 Paris, France; [email protected] (J.S.); [email protected] (M.-L.M.); [email protected] (B.F.) 3 Institut Pasteur, Emerging Diseases Epidemiology Unit, Centre for Global Health Research and Education, 75015 Paris, France; [email protected] (L.S.); [email protected] (A.F.) 4 Laboratoire Cerballiance, 75017 Paris, France; [email protected] 5 Citation: Parize, P.; Sommé, J.; Institut Pasteur, Centre Médical, Centre d’Infectiologie Necker-Pasteur, 75015 Paris, France; Schaeffer, L.; Ribadeau-Dumas, F.; [email protected] (J.C.); [email protected] (J.G.); [email protected] (P.-H.C.) 6 Benabdelkader, S.; Durand, A.; Institut Pasteur, Laboratory of the Medical Center, 75015 Paris, France; [email protected] 7 Conservatoire National des Arts et Métiers, 75003 Paris, France Tarantola, A.; Cailhol, J.; Goesch, J.; * Correspondence: [email protected]; Tel.: +33-140-613-436 Kergoat, L.; et al. -
B-Cell Reconstitution Recapitulates B-Cell Lymphopoiesis Following Haploidentical BM Transplantation and Post-Transplant CY
Bone Marrow Transplantation (2015) 50, 317–319 © 2015 Macmillan Publishers Limited All rights reserved 0268-3369/15 www.nature.com/bmt LETTER TO THE EDITOR B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY Bone Marrow Transplantation (2015) 50, 317–319; doi:10.1038/ From week 9, the proportion of transitional B cells progressively bmt.2014.266; published online 24 November 2014 decreased (not shown), whereas that of mature B cells increased (Figure 1d). To further evaluate the differentiation of mature cells, we included markers of naivety (IgM and IgD) and memory (IgG) in The treatment of many hematological diseases benefits from our polychromatic panel. At week 9, when a sufficient proportion myeloablative or non-myeloablative conditioning regimens of cells were available for the analysis, B cells were mostly naive followed by SCT or BMT. HLA-matched donors are preferred but and remained so for 26 weeks after haploBMT (Figure 1d). Despite not always available. Instead, haploidentical donors can be rapidly low, the proportion of memory B cells reached levels similar to identified. Unmanipulated haploidentical BMT (haploBMT) with that of marrow donors (Supplementary Figure 1D). non-myeloablative conditioning and post-transplant Cy has been To further investigate the steps of B-cell maturation, we developed to provide a universal source of BM donors.1 Cy, analyzed CD5, a regulator of B-cell activation, and CD21, a which depletes proliferating/allogeneic cells, prevents GVHD.1 component of the B-cell coreceptor complex, on transitional B Importantly, the infection-related mortality was remarkably low, cells. These surface markers characterize different stages of 5,6 5,6 suggesting effective immune reconstitution.1,2 However, a transitional B-cell development. -
Human B Cell Isolation Product Selection Diagram
Human B Cell Isolation Product Selection Explore the infographic below to find the correct human B cell isolation product for your application. 1. Your Starting Sample Whole Peripheral Blood/Buffy Coat PBMCs/Leukapheresis Pack 2. Cell Separation Platform Immunodensity Cell Separation Immunomagnetic Cell Separation Immunomagnetic Cell Separation 3. Product Line RosetteSep™ EasySep™ EasySep™ Sequential Selection Negative Selection Negative Selection Positive Selection Negative Selection Positive Selection 4. Selection Method (Positive + Negative) iRosetteSep™ HLA iEasySep™ Direct HLA i, iiEasySep™ HLA iEasySep™ HLA B Cell viEasySep™ Human CD19 EasySep™ Human IgG+ B Cell Enrichment Cocktail B Cell Isolation Kit Chimerism Whole Blood Enrichment Kit Positive Selection Kit II Memory B Cell Isolation (15064HLA)1, 2, 3 (89684) / EasySep™ Direct B Cell Positive Selection (19054HLA)1, 2 (17854)1, 2 Kit (17868)1 (optional), 2' HLA Crossmatch B Cell Kit (17886)1, 2 Isolation Kit (19684 - 1, 2 RosetteSep™ Human available in the US only) iiiEasySep™ Human B Cell viEasySep™ Release EasySep™ Human Memory 5. Cell Isolation Kits B Cell Enrichment Cocktail i, iiEasySep™ HLA Enrichment Kit Human CD19 Positive B Cell Isolation Kit 1, 2, 3 1, 2 1, 2 1 (optional), 2 Catalog #s shown in ( ) (15024) Chimerism Whole Blood (19054) Selection Kit (17754) (17864) EasySep™ Direct Human CD19 Positive Selection B-CLL Cell Isolation Kit Kit (17874)1, 2 1, 2, 3, 4 *RosetteSep™ Human (19664) iiiEasySep™ Human B Cell EasySep™ Human CD138 Multiple Myeloma Cell Isolation Kit -
COVID-19 Vaccination Programme: Information for Healthcare Practitioners
COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1. -
Immunity ≠ Immunological Memory
Immunity ≠ Immunological Memory Rolf Zinkernagel University of Zurich IMI Stakeholder Forum - 13 May 2013 - Brussels • Protective vaccines imitate co-evolution of infectious agents and hosts. • We cannot do better than evolution by using the same tools, only when introducing ‘new’ tools (antibiotics, antivirals, autoantibodies, behavioural changes) • Vaccines against solid tumours (carcinomas, sarcomas) and chronic persistent infections are theoretically not impossible but practically highly unlikely! Vaccines Not successful available Polio 1, 2, 3 TB bact. toxins Leprosy measles HIV Haem. infl. malaria (cholera) Neutr. / effector T cells opsonising antibodies antibodies igG (IgA) IMMUNITY • "innate resistance" > 95 % • Ab in eggs • protective memory via Ab (vaccines) • TB: no vaccine • autoimmunity > 30 y, female > male 5 : 1 • tumors > 30 years • Is what we measure biologically important ? (e.g. acad. memory: earlier + greater) CTL ELISA nAb Immunity Immunology Protection • ‚Memory‘ • Small pox • quicker - higher • Poliomeningitis • Measles • HIV, malaria - • Tuberculosis ± Antibody Memory after immunization with VSV a) neutralizing antibodies b) ELISA 12 12 ) 10 ) 10 2 3 8 8 40 log 10 log 6 - - 6 NP binding NP - 4 IND neutralizing 4 - IgG ( IgG ( 2 VSV 2 VSV 0 0 0 20 100 200 300 0 20 100 200 300 days after immunization days after immunization Why immunological Memory ? Protection (immunity) counts ! • Earlier + better • If first infection survived no need for memory • If first infection kills no need for memory • All vaccines that -
Lymphopenia-Induced Proliferation Lymphocytes During and After
The Journal of Immunology Effects of Increasing IL-7 Availability on Lymphocytes during and after Lymphopenia-Induced Proliferation1 Nabil Bosco,* Fabien Agene`s,* and Rhodri Ceredig2† IL-7 is critically involved in regulating peripheral T cell homeostasis. To investigate the role of IL-7 on lymphopenia-induced proliferation of polyclonal lymphocytes, we have transferred CFSE-labeled cells into a novel T-lymphopenic, IL-7-transgenic mouse line. Results obtained indicate that T and B cells do not respond in the same way to IL-7-homeostatic signals. Overex- pression of IL-7 enhances proliferation of both CD4؉ and CD8؉ T cells but with distinctly temporal effects. Expansion of naturally arising CD4؉-regulatory T cells was like that of conventional CD4؉ T cells. IL-7 had no effect on B cell proliferation. By immunohistology, transferred T cells homed to T cell areas of spleen lymphoid follicles. Increasing IL-7 availability enhanced T cell recovery by promoting cell proliferation and reducing apoptosis during early stages of lymphopenia-induced proliferation. Taken together, these results provide new insights into the pleiotropic effects of IL-7 on lymphopenia-induced T cell proliferation. The Journal of Immunology, 2005, 175: 162–170. espite declining thymic output with age, the peripheral T either IL-7-deficient or wild-type mice treated with anti-IL-7 or cell pool of an adult animal remains remarkably stable anti-IL-7R␣ mAb show that perturbation of IL-7 signals prevents D (1, 2). How the T cell pool is maintained remains a cen- the expansion of transferred T cells (1, 10). -
B Cells + Interaction
Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5 + B Cells This information is current as of October 2, 2021. Isaac R. Blanca, Earl W. Bere, Howard A. Young and John R. Ortaldo J Immunol 2001; 167:6132-6139; ; doi: 10.4049/jimmunol.167.11.6132 http://www.jimmunol.org/content/167/11/6132 Downloaded from References This article cites 45 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/167/11/6132.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5؉ B Cells Isaac R. Blanca,*† Earl W. Bere,* Howard A. -
Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.